Nagendran Sukumar

Nagendran Sukumar is listed in filings as President and Head of R&D at Taysha Gene Therapies, Inc.. This profile follows SEC Form 4 activity through Apr 13, 2026, including sale activity. Recent filings connect the profile to Taysha Gene Therapies, Inc. (TSHA). The current snapshot covers public activity from Dec 1, 2025 to Apr 13, 2026. Reported amounts are shown as $1.2M to $49.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.